Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical and radiographic outcomes following open Latarjet with single button technique.

JSES reviews, reports, and techniques·2026

Same author

Fluid balance during surgery: still a dilemma.

European journal of anaesthesiology·2026

Same author

Gingival and Periodontal Diseases and Conditions in Children and Adolescents: Consensus Report.

Journal of clinical periodontology·2026

Same author

Gingival and periodontal diseases and conditions in children and adolescents: consensus report.

European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry·2026

Same author

Residual Pockets as an Endpoint on Periodontal Disease Progression in Supportive Periodontal Care.

Journal of clinical periodontology·2026

Same author

Dental Biofilm-Induced Gingivitis in Children and Adolescents Without Known Systemic Involvement: A Systematic Review.

Journal of clinical periodontology·2026

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

[Recombinant activated factor VII for perioperative bleeding].

Rodrigo López¹, Nicolás Aeschlimann, Claudia Carvajal

¹Departamento de Anestesiología, Hospital Clínico Pontificia Universidad Católica de Chile, Santiago, Chile. ralopez@puc.cl

Revista Medica De Chile

|September 12, 2009

Summary

This summary is machine-generated.

Recombinant activated factor VII (rFVIIa) reduces bleeding episodes when used prophylactically. Adverse events are linked to patient disease severity and other treatments, not solely rFVIIa.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Experiment Videos

Last Updated: Jun 20, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

Hematology
Pharmacology
Surgical Hemostasis

Background:

Recombinant activated factor VII (rFVIIa) is a hemostatic agent initially for hemophilia.
Its application has expanded to perioperative bleeding and other conditions.

Purpose of the Study:

To review the efficacy and safety of rFVIIa in various bleeding scenarios.
To outline current recommendations for its clinical use.

Main Methods:

Literature review of studies on rFVIIa use.
Analysis of prophylactic and therapeutic applications.
Evaluation of adverse event profiles and risk factors.

Main Results:

Prophylactic rFVIIa decreases bleeding episodes but does not alter transfusion requirements.
Thromboembolic events are associated with underlying disease severity and concomitant hemostatic agents.
rFVIIa is recommended for persistent bleeding post-product transfusion after excluding surgical causes.

Conclusions:

rFVIIa is effective in reducing bleeding episodes, with risks primarily linked to patient-specific factors.
Clinical use should be guided by specific indications, risk assessment, and cost considerations.